Clinical trial
A Phase 3 Randomized, Placebo-controlled, Double-blind, Parallel-group Program to Evaluate Efficacy and Safety of Filgotinib in Adult Subjects With Active Axial Spondyloarthritis
NCT05785611 is registered in ClinicalTrials.gov with Alfasigma S.p.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Placebo-controlled, Double-blind, Parallel-group Program to Evaluate Efficacy and Safety of Filgotinib in Adult Subjects With Active Axial Spondyloarthritis
- Lead sponsor
- Alfasigma S.p.A.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- April 5, 2023
- Completion date
- December 31, 2028
- Enrollment
- 495 (actual)
- Sites
- 123
Conditions
As the registry lists them; a condition with its own page is linked.